Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
9.2100
0.00 (0.00%)
Rocket Pharmaceuticals Inc is a biotechnology company focused on developing innovative gene therapies to treat rare and devastating diseases
Its mission revolves around leveraging advanced genetic science and technology to create transformative therapies that can address the underlying causes of genetic disorders. The company primarily targets conditions that currently lack effective treatment options, with the aim of providing significant clinical benefits and improving the quality of life for patients. By utilizing cutting-edge research and collaborating with leading experts in the field, Rocket Pharmaceuticals strives to bring groundbreaking solutions to the forefront of healthcare.
Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC information.
Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming.
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500, also rose, gaining, 0.01% to 4,462.11.
Avalo Therapeutics, Inc. (NASDAQAVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of $0.10/less for 10 consecutive trading days.
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 50 points on Wednesday. The Dow traded up 0.16% to 34,701.06 while the NASDAQ rose 0.44% to 13,834.85. The S&P 500, also rose, gaining, 0.30% to 4,475.23.
On Tuesday, Rocket Pharmaceuticals Inc (NASDAQRCKT) announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501
